Compare Abbott Laboratories (ABT) vs VanEck Australian Floating Rate ETF (FLOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs VanEck Australian Floating Rate ETF — how do they compare? Abbott Laboratories trades at $109.23 (market cap $187.95B), while VanEck Australian Floating Rate ETF trades at $50.93. The key difference: Abbott Laboratories pays a 2.32% dividend while VanEck Australian Floating Rate ETF pays none. Which is the better fit depends on your goals.
| ABT | FLOT | |
|---|---|---|
Market Cap | $187.95B | — |
Sector | Health | Sector/Thematic |
52-Week High | $136.62 | $51.09 |
52-Week Low | $82.57 | $50.72 |
Enterprise Value | $214.96B | — |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $109.74, up 1.8% on the day, with a bullish technical signal from moving averages and strong analyst consensus. Recent financials show revenue growth to $44.33 billion in 2025, though net income declined to $6.52 billion. Key developments include a CE Mark for dual glucose-ketone sensors, enhancing its diabetes care portfolio. The stock is near its 52-week high, with support at $108 and resistance at $109.
Outlook remains positive with a consensus price target of $120.70, offering ~10% upside. Risks include competitive pressures in medical devices and macroeconomic volatility. Earnings beats in Q1 and Q2 2026 support growth, but margin compression and high P/E of 35.15 warrant caution for value-focused investors.
FLOT, the iShares Floating Rate Bond ETF, trades at $50.93, showing minimal daily movement. The technical outlook is bearish based on moving averages, though oscillators are neutral. Recent news highlights its role as a potential hedge against rising interest rates, with a focus on high credit quality and a 4.0% SEC yield. Dividend payments are consistent, with recent distributions around $0.17-$0.18 per share.
The outlook for FLOT is cautiously positive if the Federal Reserve raises rates, as its floating rate structure could benefit income growth. Risks include credit quality deterioration and persistent inflation without Fed action. Analyst sentiment is generally neutral, viewing it as a stable short-term cash alternative rather than a growth vehicle.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About VanEck Australian Floating Rate ETF
FLOT provides exposure to a diversified portfolio of Australian dollar-denominated floating rate notes. It tracks the Bloomberg AusBond Credit FRN 0+ Yr Index, focusing on high-quality, investment-grade bonds from top Australian banks and financial institutions.
Read more on FLOT →
